Simplification of continuous infusion of glucose with model assessment in the evaluation of insulin resistance in women with PCOS

References

• Poison DW, Adams J, Wadsworth J, et al. Polycystic ovaries — a common finding in normal women. Lancet 1988;1:870–2
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ, Kahsar-Miller M, etal. Prevalence of the polycystic ovary syndrome in unselected black and white women of the south-eastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078–82
   Google Scholar
• Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41: 1257–66
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801–10
   Google Scholar
• Dale PO, Tanbo T, Vaaler S, et al. Body weight, hyperinsulineamia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992;58:487–91
   PubMed Web of Science ®Google Scholar
• Dale PO, Tanbo T, Haug E, et al. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod 1998;13:567–70
   PubMed Web of Science ®Google Scholar
• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986;293:355–9
   Google Scholar
• Hull MGR. Epidemiology of infertility and poly-cystic ovarian disease: Endocrinological and demo-graphic studies. Gynecol Endocrinol 1987;1:235–45
   PubMedGoogle Scholar
• Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, con-trolled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–9
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction — evaluated from a risk factor model based on a prospective study ofwomen. Acta Obstet Gynecol Scand 1992;71:599–604
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteride DJ, et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol 1992;37:119–25
   PubMed Web of Science ®Google Scholar
• Robinson S, Henderson AD, Gelding SV, et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996;44:277–84
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakobowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, etal. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81: 3299–306
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syn-drome. J Clin Endocrinol Metab 1997;82:2108–16
   PubMed Web of Science ®Google Scholar
• Hosker JP, Matthews DR, Rudenski AS, et al. Continuous infusion of glucose with model assess-ment: measurement of insulin resistance and I3-cell function in man. Diabetologia 1985;28:401–11
   PubMed Web of Science ®Google Scholar
• Bergman RN, Finegood D, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985;6:45–86
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and I3-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28: 412–9
   PubMed Web of Science ®Google Scholar
• Bonora E, Moghetti P, Zancanaro C, et al. Estimates of in vitro insulin action in man: com-parison of insulin tolerance test with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 1989;68:374–8
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214–23
   Google Scholar
• Bergman RN, Prager R, Volund A, et al. Equivalence of the insulin sensitivity index in man derived from the Minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79: 790–800
   PubMed Web of Science ®Google Scholar
• Bergman RN. Toward physiological understand-ing o f gluco se tolerance. Minimal-model approach. Diabetes 1989;38:1512–27
   Google Scholar
• Levy JC, Rudenski AS, Burnett MA, et al. Simple empirical assessment of I3-cell function by a constant infusion of glucose test in normal and Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1991;34:488–99
   PubMed Web of Science ®Google Scholar
• Rudenski AS, Matthews DR, Levy JC, et al. Understanding 'insulin resistance': both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991;40: 908–17
   PubMed Web of Science ®Google Scholar
• Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942–7
   PubMed Web of Science ®Google Scholar
• Legro RS, Finegood D, DunaifA. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694–8
   Google Scholar
• Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–10
   PubMed Web of Science ®Google Scholar
• Parra A, Ramirez A, Espiosa de los Monteros A. Fasting glucose/insulin ratio. An index to differen-tiate normal from hyperinsulinemic women with polycystic ovary syndrome. Rev Invest Clin 1994; 46:363–8
   Google Scholar
• Lasskso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959–65
   PubMedGoogle Scholar
• Mykkanen L, Haffner SM, Ronnemaa T, et al. Relationship of plasma insulin concentration and insulin sensitivity to blood pressure. Is it modified by obesity? J Hypertens 1996;14:399–405
   Google Scholar
• Boyko EJ, Leonetti DL, Bergstrom RW, et al. Low insulin secretion and high fasting insulin and C-peptide levels predict increased visceral a diposity. 5-year follow-up among initially nondiabetic Japanese-American men. Diabetes 1996;45:1010–5
   PubMedGoogle Scholar
• Tropeano G, Lucisano A, Liberale I, et al. Insulin, C-peptide, androgens and I3-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1994;78:305–9
   PubMedGoogle Scholar
• Matthews DR, Lang DA, Burnett MA, et al. Control of pulsatile insulin secretion in man. Diabetologia 1983;24:231–7
   PubMed Web of Science ®Google Scholar